Associate Director at GSK, United States
Rushit N. Lodaya is an accomplished leader in vaccine formulation and drug product R&D, with over a decade of expertise in developing innovative delivery platforms for nucleic acids, adjuvants, and protein antigens. He specializes in lipid nanoparticle (LNP) formulations for RNA delivery, optimizing thermostable formulations, and advancing alternative drying technologies. His contributions include multiple patents, impactful publications, and leadership roles in cross-functional collaborations, including partnerships with organizations like the NIH. A strong advocate for innovation, Rushit has significantly influenced the fields of mRNA vaccines and adjuvant development through his research and mentorship. He emphasizes a “patent-first” strategy while promoting knowledge sharing through guest editing and academic collaborations. Dedicated to sustainability and translational research, he integrates cutting-edge science with practical applications. Rushit’s leadership, scientific contributions, and commitment to fostering talent make him a standout researcher advancing the frontiers of biopharmaceuticals and vaccine technology.
Professional Profile
Education
Rushit N. Lodaya has a strong academic foundation that underpins his expertise in pharmaceutical and vaccine research. He earned his Ph.D. from Northeastern University, Boston, as a GSK Fellow, where his research focused on developing and characterizing novel self-emulsifying adjuvant systems containing α-tocopherol. Under the guidance of Dr. Mansoor M. Amiji and Dr. Derek T. O’Hagan, he conducted innovative studies to enhance immune responses in vaccine formulations, including in vivo evaluations of adjuvants and lyophilization processes for single-vial vaccines. Prior to this, he pursued undergraduate research at Mumbai University, where he formulated and evaluated sustained-release drug delivery systems. His educational journey is marked by a blend of rigorous academic research and practical applications, equipping him with a robust skill set in formulation sciences, drug delivery, and vaccine development. This educational background laid the groundwork for his impactful career in advancing cutting-edge pharmaceutical and biopharmaceutical technologies.
Professional Experience
Rushit N. Lodaya has over a decade of professional experience in pharmaceutical and biopharmaceutical research, specializing in vaccine formulation, drug delivery systems, and lipid nanoparticle (LNP) technologies. Currently serving as Associate Director of RNA Delivery Sciences at GSK Vaccines, he leads strategies to advance mRNA delivery platforms and novel characterization tools. Previously, as an Expert Scientist at GSK, he spearheaded initiatives to optimize mRNA-LNP formulations, improve vaccine adjuvant processes, and establish external collaborations for drug product innovation. His earlier roles include significant contributions to Phase III clinical development, process transfer for GMP manufacturing, and formulation of protein antigens. At Cubist Pharmaceuticals, he worked on early-stage formulations for novel antibiotics and post-operative pain management. Rushit’s experience also encompasses academic roles, supervising Ph.D. students and guest editing for journals. His dynamic career blends technical expertise, innovative research, and leadership, driving advancements in vaccine and therapeutic development to address critical global health needs.
Research Interests
Rushit N. Lodaya’s research interests lie at the intersection of vaccine formulation science, advanced drug delivery systems, and pharmaceutical innovation. He is particularly focused on developing lipid nanoparticle (LNP) platforms for RNA delivery, optimizing their composition, stability, and scalability for clinical applications. His work extends to creating novel adjuvants and understanding their mechanisms to enhance immune responses. Rushit is also deeply invested in exploring alternative drying technologies, such as lyophilization, to achieve thermostable formulations, crucial for vaccines’ global accessibility and distribution. He is enthusiastic about tackling challenges in intracellular delivery, improving endosomal escape, and enabling co-delivery systems for therapeutic and prophylactic applications. Committed to translational research, Rushit seeks to bridge the gap between preclinical discoveries and real-world implementation, addressing pressing public health needs. His passion for innovation and sustainability aligns with his goal of advancing next-generation biopharmaceuticals and vaccines that are efficient, stable, and globally impactful.
Awards and Honors
Rushit N. Lodaya has been recognized for his outstanding contributions to vaccine research and pharmaceutical sciences through various awards and honors. As a recipient of the prestigious GSK Fellowship during his Ph.D. at Northeastern University, he demonstrated exceptional research capabilities in adjuvant systems and vaccine delivery. His innovative work has earned him multiple patents, including breakthroughs in lipid nanoparticle formulations and freeze-dried RNA vaccines, highlighting his commitment to advancing cutting-edge technologies. Rushit has also been invited to serve as a guest editor for a special issue of MDPI Pharmaceutics, focusing on next-generation vaccine adjuvants, reflecting his thought leadership in the field. His role as a mentor and collaborator has further solidified his reputation, as he supervises Ph.D. students and contributes to the scientific community through impactful publications and book chapters. These accolades underscore his dedication to innovation, collaboration, and advancing pharmaceutical sciences to address global health challenges.
Conclusion
Rushit N. Lodaya is a highly suitable candidate for the Best Researcher Award. His exceptional contributions to vaccine formulation, particularly in mRNA and LNP technologies, and his leadership in advancing innovative drug product solutions make him a strong contender. While he can expand his translational and collaborative impact, his sustained excellence, significant patents, publications, and mentorship strongly align with the award’s goals. Recognizing his efforts would celebrate and encourage further advancements in the critical field of vaccine R&D.
Publications top noted
- The continued advance of vaccine adjuvants–‘we can work it out’
- Authors: DT O’Hagan, RN Lodaya, G Lofano
- Year: 2020
- Citations: 117
- “World in motion”–emulsion adjuvants rising to meet the pandemic challenges
- Authors: DT O’Hagan, R van der Most, RN Lodaya, M Coccia, G Lofano
- Year: 2021
- Citations: 73
- Formulation design, optimization and in vivo evaluations of an α-tocopherol-containing self-emulsified adjuvant system using inactivated influenza vaccine
- Authors: RN Lodaya, AP Kanitkar, K Friedrich, D Henson, R Yamagata, S Nuti, …
- Year: 2019
- Citations: 26
- Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant
- Authors: Y Wen, HV Trinh, CE Linton, C Tani, N Norais, DA Martinez-Guzman, …
- Year: 2018
- Citations: 17
- Stable nanoemulsions for the delivery of small molecule immune potentiators
- Authors: RN Lodaya, LA Brito, TYH Wu, AT Miller, GR Otten, M Singh, DT O’Hagan
- Year: 2018
- Citations: 14
- Overview of vaccine adjuvants
- Authors: RN Lodaya, S Gregory, MM Amiji, DT O’Hagan
- Year: 2022
- Citations: 7
- Practical aspects of vaccine development
- Authors: P Kolhe, S Ohtake
- Year: 2021
- Citations: 5
- A Self-Emulsified Adjuvant System Containing the Immune Potentiator Alpha Tocopherol Induces Higher Neutralizing Antibody Responses than a Squalene-Only Emulsion When Evaluated
- Authors: RN Lodaya, AP Kanitkar, A Ashraf, D Bamba, MM Amiji, DT O’Hagan
- Year: 2023
- Citations: 3
- Lyophilized vaccine development
- Authors: NM Payton, RN Lodaya, AM Padilla
- Year: 2022
- Citations: 3
- Nanoscale Vaccines for Influenza
- Authors: S Bhangde, RN Lodaya, MM Amiji
- Year: 2023
- Citations: 1
- Microfluidic-Chip-Based Formulation and In Vivo Evaluations of Squalene Oil Emulsion Adjuvants for Subunit Vaccines
- Authors: S Bhangde, S Fresnay-Murray, T Garretson, A Ashraf, DT O’Hagan, …
- Year: 2024
- Citations: Not yet available
- Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
- Authors: R Lodaya, P Pohlhaus, E Zecca, J Zhang, A Padilla, E Bourlès, J Enert
- Year: 2024
- Citations: Not yet available
- “World in motion”-emulsion adjuvants rising to meet the pandemic challenges (Vol 6, 158, 2021)
- Authors: DT O’Hagan, R van der Most, RN Lodaya, M Coccia, G Lofano
- Year: 2023
- Citations: Not yet available
- Author Correction: “World in motion”–emulsion adjuvants rising to meet the pandemic challenges
- Authors: DT O’Hagan, R van der Most, RN Lodaya, M Coccia, G Lofano
- Year: 2023
- Citations: Not yet available
- Review 2: “A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability”
- Authors: HM Niknam, NS Savar
- Year: 2022
- Citations: Not yet available
